Eli Lilly has introduced Mounjaro (tirzepatide), its innovative diabetes and weight-loss medication, to the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). This once-weekly injectable is priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial, offering a more affordable option compared to its U.S. pricing of approximately $1,000 per month.Mounjaro functions by mimicking the effects of two natural hormones, GLP-1 and GIP, to regulate appetite, blood sugar, and digestion, leading to reduced food intake and improved insulin sensitivity. Clinical trials have demonstrated significant weight loss among users, with adults taking Mounjaro, combined with diet and exercise, losing an average of 21.8 kg at the highest dose over 72 weeks.India faces a growing public health challenge, with approximately 101 million individuals living with diabetes and an adult obesity prevalence of around 6.5%, affecting nearly 100 million people as of 2023. Obesity is linked to over 200 health complications, including hypertension, coronary heart disease, and obstructive sleep apnea. The introduction of Mounjaro is expected to intensify competition in India’s anti-obesity drug market, which has seen exponential growth, expanding from ₹137 crore in November 2020 to ₹535 crore in November 2024. Other pharmaceutical companies, such as Novo Nordisk, Sun Pharmaceutical, and Biocon, are also developing similar treatments to capture this burgeoning market.
While Mounjaro offers a new avenue for treatment, medical professionals caution that it is not suitable for all diabetic patients and should be used under proper medical supervision. The drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbid condition.
Eli Lilly’s strategic pricing for Mounjaro in India reflects the company’s commitment to expanding access to innovative treatments in the country. As the demand for effective diabetes and obesity management solutions grows, Mounjaro’s entry into the Indian market represents a significant development in addressing these pressing health issues.
